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ABSTRACT 
 
An alternative strategy to the use of in vitro expanded cells in regenerative 
medicine is the use of freshly isolated stromal cells, where a bioactive scaffold is 
used to provide an environment conductive to proliferation and tissue-specific 
differentiation in vivo.   The objective of this study was to develop a cartilage 
extracellular matrix (ECM) derived scaffold that could facilitate the rapid proliferation 
and chondrogenic differentiation of freshly isolated stromal cells. By freeze-drying 
cryomilled  cartilage  ECM of  differing concentrations, it was possible  to  produce 
scaffolds with a range of pore sizes. The migration, proliferation and chondrogenic 
differentiation of infrapatellar fat pad derived stem cells (FPSCs) depended on the 
concentration/porosity of these scaffolds, with greater sGAG accumulation observed 
in scaffolds with larger sized pores. We then sought to determine if freshly isolated 
fat pad derived stromal cells, seeded onto a TGF-β3 eluting ECM-derived scaffold, 
could promote chondrogenesis in vivo. While a more cartilage-like tissue could be 
generated using culture expanded FPSCs compared to non-enriched freshly isolated 
cells, fresh CD44
+  
stromal cells were capable of producing a tissue in vivo that 
 
stained  strongly  for  sGAGs  and  type  II  collagen.  These  findings  open  up  new 
possibilities for in-theatre cell based therapies for joint regeneration.
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1. INTRODUCTION 
 
 
Cartilage regeneration is still a major challenge in orthopaedic medicine. The 
outcomes of cartilage repair procedures are inconsistent and further joint 
degeneration commonly occurs.[1,2]  Cell based therapies such as autologous 
chondrocyte implantation (ACI) may lead to improved clinical outcomes for patients, 
however the high cost and need for two hospital stays have limited the widespread 
adoption of this technique into the clinic.[3]  This has motivated increased interest in 
single-stage or off-the-shelf therapies for cartilage regeneration, possibly involving 
the use of freshly isolated cells that can potentially be harvested in-theatre and 
delivered back into the patient during the same procedure.[4] Successful realization of 
such a concept therefore requires the identification of both a suitable cell source and 
the development of bioactive scaffolds capable of promoting the rapid proliferation 
and chondrogenic differentiation of the limited number of cells that can potentially be 
isolated from a patient in-theatre. 
Extracellular matrix (ECM) derived from native tissue has been proposed as a 
promising biological scaffold material, providing cues that enhance cell proliferation, 
differentiation and matrix formation.[5,6]  The ECM of articular cartilage is organized 
into a complex three-dimensional network, consisting primarily of type II collagen and 
proteoglycans  in  which  growth  factors  and   other  cues  are  incorporated.[1,7] 
Devitalised and decellularized ECM-derived from articular cartilage has been used to 
produce  bioactive  scaffolds  for  cartilage  tissue  engineering  applications.[5,7-10,11] 
 
These scaffolds have been shown to be chondro-inductive in vitro,[8]  although their 
capacity to promote the development of functional hyaline cartilage is enhanced 
when additionally stimulated with exogenous growth factors such as transforming 
growth factor (TGF)-β3.[7,12]  We have previously demonstrated that cartilage ECM-
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derived scaffolds can also be used to control the delivery and release of TGF-β3 to 
stem cells,[7] opening up the potential of using such biomaterials as part of an off-the- 
shelf  strategy for joint regeneration. While cartilage  ECM is clearly a  promising 
material   for   the   development   of   scaffolds   for   cartilage   tissue   engineering 
applications, it is still unclear what the optimal composition and architecture (e.g. 
pore size) of such scaffolds should be to promote robust chondrogenesis. Given that 
such factors have been shown to play a key role in regulating cell fate in other 
scaffolding systems,[13,14]  it would seem highly likely that scaffold composition and 
pore size would need to be tailored to promote the rapid proliferation and 
chondrogenic differentiation of any progenitor cell population intended to be used as 
part of a single-stage therapy for cartilage regeneration. 
The overall goal of this study was to develop a  single-stage strategy for 
promoting chondrogenesis in vivo that combines an optimised cartilage ECM-derived 
scaffold and freshly isolated infrapatellar fat pad derived stromal cells. The 
infrapatellar fat pad was chosen as a source of stromal cells as it is easily accessible 
to a clinician during joint repair procedures. Furthermore, infrapatellar fat pad derived 
stem cells (FPSCs) have been shown to have a strong chondrogenic potential and 
can be used to engineer functional cartilaginous grafts.
[15,16] 
The objective of the first 
 
phase of the study was to develop cartilage ECM-derived scaffolds with controllable 
and consistent pore size and shape, and to then explore how altering their porosity 
influences the migration, proliferation and chondrogenic differentiation of human 
FPSCs that are seeded onto such constructs. We then explored the potential of such 
scaffolds to act as growth factor delivery systems to facilitate chondrogenesis of 
culture expanded FPSCs in vitro and in vivo. Finally, we sought to determine if such
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a scaffold could be coupled with enriched freshly isolated stromal cells as a one-step 
or single-stage strategy for promoting chondrogenesis in vivo. 
 
2. MATERIAL AND METHODS 
 
 
2.1. Scaffold preparation 
 
 
Cartilage used in the fabrication of ECM-derived scaffolds was harvested, 
under sterile conditions, from the femoral condyles and patella groove of three month 
old female pigs (n=3). The porcine breed from maternal side (50%) was: half 
Landrace, a quarter Duroc and a quarter Large White. The terminal side (50%) was: 
PIC Line 337. ECM was pooled before use. The cartilage was first sectioned into 
small pieces using a scalpel. These cartilage pieces were then fragmented using two 
different methods, to produce either “coarse” or “fine” scaffolds. Coarse scaffolds 
were produced using a previously described protocol,[7] where cartilage is blended in 
deionised water (dH2O) using an homogeniser (IKAT10, IKA Works Inc, NC, USA) to 
create a cartilage slurry. The homogenized tissue was centrifuged and the 
supernatant was removed. The remaining material was re-suspended in dH2O at a 
given concentration (500 mg ml-1). 
 
Fine scaffolds were fabricated by first pulverising cartilage pieces within a 
cryogenic mill (6770 Freezer/Mill, SPEX, UK). These particles of cartilage where 
then blended in dH2O using a homogenizer (IKAT10, IKA Works Inc, NC, USA) to 
create a fine cartilage slurry. Three distinct scaffolds were fabricated using different 
slurry concentrations (250 mg ml-1; 500 mg ml-1; 1000 mg ml-1). 
The slurry for both coarse and fine groups was transferred to custom made 
 
moulds (containing wells 5 mm in diameter and 3 mm in height) and freeze-dried 
(FreeZone Triad, Labconco, KC, USA) to produce porous scaffolds, as previously 
described.[7] Briefly, the slurry was frozen to -30˚C (1˚C min-1) and maintained at that
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temperature for one hour. The temperature was then increased to -10˚C (1˚C min-1) 
and held for 24 hours before being increased to room temperature (0.5˚C min-1). 
Next,  two  different  crosslinking  techniques  were  applied  to  the  scaffolds.  The 
scaffolds underwent dehydrothermal (DHT) and 1-Ethyl-3-3dimethyl aminopropyl 
carbodiimide (EDAC) crosslinking as previously described in literature.[7,17] The DHT 
process was performed in a vacuum oven (VD23, Binder, Germany), at 115˚C and 2 
mbar for 24 hours. The EDAC (Sigma-Aldrich, Germany) crosslinking consisted of 
chemical exposure (2 hours; 6 mM) in the presence of N-Hydroxysuccinimide (NHS) 
(Sigma-Aldrich, Germany), a catalyst that is commonly used with EDAC. A molar 
ratio of 2.5 M EDAC/M N-Hydroxysuccinimide was used. [17,18] 
 
2.2. Helium ion microscopy (HIM) and Light Microscopy 
 
 
Devitalized ECM-derived scaffolds were imaged using Helium ion microscopy 
(HIM) (Zeiss Orion Plus, Germany) as previously described.[7]  Image resolution of 
the microscope was 0.35 nm, with a working distance of 10 mm and a 10 µm 
aperture. Beam current was 0.8 pA with a tilt angle of 15˚. Charge compensation 
was enabled using an electron beam flood gun. No conductive coating of the 
specimens was employed. The main goal of this step was to confirm and compare 
scaffold porosity between the different groups. Routine light microscopy was also 
used for morphometrical and histological analysis. 
 
2.3. Diameter, particle size, pore size determination and mechanical testing 
 
 
After the 4 weeks culture period, constructs were removed from culture wells 
and imaged. Macroscopic images were analyzed with Image J to quantify changes in 
construct  diameter  (n=4)  and  particle  size.  As  previously  described,  pore  size
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determination for the scaffolds was obtained by measuring the diameter of 40 pores 
 
(with Image J) in HIM micrographs of dry scaffolds (n=3) before cell seeding.[19] 
 
Scaffolds were mechanically tested dry using a standard materials testing 
machine with a 5 N load cell (Zwick Z005, Roell, Germany).[16]    A preload of 0.03N 
was applied to ensure direct contact between the scaffold and the loading platens. A 
ramp compressive strain of 10% was applied to samples, from which the Young’s 
modulus  was  determined  from  the  slope  of  the  stress-strain  curve.  Engineered 
tissues  at day 28  were  tested  using  a  similar  protocol,  except constructs  were 
hydrated and maintained in a bath of  phosphate buffered saline  (PBS) (Sigma- 
Aldrich, Germany). 
 
2.4. Cell culture 
 
 
Ethical approval for the isolation of human FPSCs was obtained from the 
institutional  review board  of  the  Mater  Misericordiae  University  Hospital,  Dublin, 
Ireland.  Cells  were  isolated  from  the  infrapatellar  fat  pad  of  patient  (Female, 
diseased donor, age 52) undergoing total joint arthroplasty. The fat pad was 
harvested, weighed and washed thoroughly in PBS (Sigma-Aldrich, Germany). Next, 
the tissue was diced in sterile conditions followed by rotation at 37˚C in high-glucose 
Dulbecco’s Modified Eagle Medium (hgDMEM, GlutaMAXTM)(GIBCO, Biosciences, 
Ireland)  containing  collagenase  type  II  (750  U  ml-1,  Worthington  Biochemical, 
 
LaganBach Services, Ireland) and 1% penicillin (100 U ml-1)-streptomycin (100 µg 
ml-1) for approximately 4 hours. A ratio of 4 ml of collagenase (750 U ml-1) per gram 
of tissue was found to be optimal based on previous work.[20, 21] After digestion, cells 
were washed, filtered (40 µm nylon cell strainer) and centrifuged (650 g; 5 minutes). 
The supernatant was removed. The remaining cells were re-suspended, counted 
and finally plated (5000 cells cm-2) in T-175 flasks (Sarsted, Wexford, Ireland). Cells
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were cultured in a standard media formulation, which consisted of hgDMEM 
containing 10% foetal bovine serum and 1% penicillin (100 U ml-1)-streptomycin (100 
mg ml-1) (GIBCO, Biosciences, Ireland) with the addition of fibroblast-growth factor-2 
(FGF-2, 5 ng ml-1; ProSpec-Tany TechnoGene Ltd, Israel). Cells were expanded to 
passage 2 (P2), with an initial seeding density of 5000 cells cm-2  at each passage. 
Media changes were performed twice weekly. 
For in vitro studies, each scaffold was seeded with 0.5x106  human FPSCs. 
Constructs were maintained in chemically defined chondrogenic medium (CDM), as 
previously described, for 28  days (5% O2;  37˚C).
[21]   CDM consisted  of    DMEM 
GlutaMAXTM supplemented with penicillin (100 U ml-1)-streptomycin (100 µg ml-1) 
 
(both GIBCO, Biosciences, Ireland), sodium pyruvate (100 µg ml-1), L-proline (40 µg 
ml-1), L-ascorbic acid-2-phosphate (50 µg ml-1), bovine serum albumin (BSA) (1.5 mg 
ml-1), insulin-transferrin-selenium (1x), dexamethasone (100 nM) (all from Sigma- 
Aldrich, Ireland) and  recombinant human transforming growth factor-β3  (TGF-β3; 
ProSpec-Tany TechnoGene Ltd, Israel) (10 ng ml-1). Groups termed “loaded with 
TGF-β3” were not supplemented with TGF-β3 in chondrogenic media during the 
culture period. Instead, TGF-β3 (approximately 5 ng in 40 µl of media) was soak- 
loaded  into  the  scaffold  and  was  not  directly  added  to  the  culture  media.  The 
scaffolds were maintained in 12 well plates and each scaffold was placed within 
cylindrical agarose moulds. After seeding, the scaffolds with the cells plus CDM (40 
µl) were left in the incubator for two hours. After two hours, supplemented CDM (2.5 
ml) was added to each well. Media changes were performed twice  weekly. The 
media was stored (-85˚C) for further analysis.
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2.5. Biochemical analysis 
 
Constructs were biochemically analyzed at day 0 and 28, for DNA content, 
sulphated glycosaminoglycan (sGAG) and collagen content, as previously 
described.[16] Briefly, constructs were enzymatically digested by incubation in papain 
(125 μg ml-1) in sodium acetate (0.1 M), cysteine HCl (5 mM), 
Ethylenediaminetetraacetic acid (EDTA) (0.05 M), pH 6.0 (all from Sigma-Aldrich, 
 
Ireland) at 60˚C under rotation (10 rpm; 18 hours). As previously described, DNA 
content of each sample was quantified using the Hoechst Bisbenzimide 33258 dye 
assay, with a calf thymus DNA standard.[19] The proteoglycan content was estimated 
by quantifying the sGAG in constructs using the dimethylmethylene blue dye-binding 
assay (Blyscan, Biocolor Ltd., Northern Ireland), using bovine chondroitin sulphate 
as a  standard.  Collagen  content  in  the  constructs  was  quantified  by measuring 
hydroxyproline content, after acidic hydrolysis of the samples (110°C; 18 hours) in 
concentrated HCL (38%). Samples were assayed using a chloramine-T assay 
assuming a hydroxyproline/collagen ratio of 1:7.69. [20] 
 
2.6. Cell viability and distribution 
 
 
Cell survival and distribution were assessed using live/dead staining for all 
slurry concentrations. Calcein was used to stain live cells and images were taken 
using  confocal  microscopy  after  2  hours  of  culture,  as  previously  described.[19] 
Briefly, at day 1 and 28, cell viability was assessed by LIVE/DEAD®  kit (Invitrogen, 
 
Bio-science, Ireland). Constructs were washed in PBS, sectioned in half, incubated 
in calcein (2 μM) (live/green) and ethidium homodimer-1 (4 μM) (dead/red) 
(Cambridge  Biosciences,  UK).  Constructs  were  washed  again  and  imaged  in 
confocal microscope 10x Olympus FV-1000 Point-Scanning Microscope (Southend-
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on-Sea,  UK)  at 515 and  615  nm  channels  and  analysed  using  FV10-ASW  2.0 
 
Viewer. 
 
 
2.7. Histology and immunohistochemistry 
 
 
Constructs were fixed overnight (4˚C) in a solution of paraformaldehyde (4%) 
(Sigma-Aldrich, Ireland), followed by washing in PBS (Sigma-Aldrich, Ireland), 
dehydrated and wax embedded. Wax embedded constructs were sectioned to 
produce 6 µm thick slices and mounted on microscope slides. Sections were stained 
with 1% alcian blue 8GX (Sigma-Aldrich) in HCl (0.1 M) for sGAG and with picro- 
sirius red for collagen. Cell nuclei were also stained with 0.1% nuclear fast red 
solution (Sigma-Aldrich). With the aim of monitoring the newly formed sGAG, 
constructs were histologically analysed (alcian blue) at day 0, 7, 14 and 28. As 
previously  described,[21]   immunohistochemical  analysis  was  performed  on  6  µm 
 
sections using monoclonal antibody to type II collagen (Abcam, UK). Samples were 
washed in PBS and subjected to peroxidase activity (20 minutes), incubated (1 hour, 
37˚C in a moist environment) with chondroitinase ABC (Sigma, 0.25 U ml-1) with the 
 
aim of enhancing the permeability of the ECM by removing the chondroitin sulphate. 
Slides were rinsed with PBS and blocked with 10% goat serum (30 minutes) and 
incubated with mouse monoclonal anti-collagen type II diluted 1:100  (1 mg ml-1; 1 
hour at RT) (Abcam, UK). A secondary antibody for type II collagen (1 mg ml-1; 1 
 
hour) (Anti-Mouse IgG Biotin antibody produced in goat) binding was then applied. 
By using Vectastain ABC reagent (Vectastain ABC kit, Vector Laboratories, UK) for 5 
minutes in peroxidase DAB substrate kit (Vector laboratories, UK), it was possible to 
observe a colour alteration. Samples were dehydrated  with  graded ethanol and 
xylene and mounted with Vectamount medium (Vector Laboratories, UK). Positive
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and negative controls (porcine cartilage and ligament) were included in the 
immunohistochemistry staining protocol for each batch.[16] 
 
2.8. ELISA - TGF-β3 release to the media 
 
 
The amount of TGF-β3 release from the growth factor loaded cartilage ECM- 
derived scaffold was determined via ELISA, as previously described [7,22]. 96 well 
plates were coated with capture antibody (360 µg ml-1) with mouse anti-human TGF- 
β3  (R&D  Systems,  UK).    The  samples  (8  time  points)  and  TGF-β3  standards 
(ProSpec-Tany TechnoGene Ltd, Israel) were incubated for 2 hours. After washing 
and drying, detection antibody (18 µg ml-1  of biotinylated goat anti-human TGF-β3) 
was added to the plate and incubated (2 hours). The next step was to wash, dry and 
incubate the plate in streptavidin-HRP (horseradish-peroxidase) (R&D Systems, UK) 
for 20 minutes in the dark. Substrate solution (1:1 mixture of H2O2  and 
tetramethylbenzidine; R&D Systems, UK) was added to each well, followed by 
incubation (20 minutes) avoiding direct light. Stop  solution  (2 N H2SO4; Sigma- 
Aldrich, Germany) was added and the optical density was determined immediately 
with a plate reader set to 450 nm. 
 
2.9. In vivo and cell population enrichment 
 
ECM-derived (DHT+EDAC crosslinked) scaffolds loaded with 5 ng of TGF-β3 
were seeded as follow: 1. No cells; 2. monolayer expanded (Passage 2) FPSCs; 3. 
FPSCs; 4. CD44+ FPSCs. All cells were isolated from porcine (female, 3 month old) 
infrapatellar fat pad and  each  scaffold was  seeded  with  0.5x106  cells,  with  the 
exception of  CD44+  where  the  number  was  0.1x106   (approximately  10% of  the 
 
freshly isolated fraction). CD44+  cells were isolated using magnetic-activated cell 
sorting (MACS®, Miltenyi Biotec, Germany). Briefly, CD44+  cells were labelled with
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micro-beads specific to CD44 according to the manufacturer’s instructions. This cell 
suspension was then passed through a MACS column in a magnetic field. 
Magnetically labelled cells CD44+ cells can be separated after removing the magnet. 
Within 24 hours of cell isolation, seeded constructs were subcutaneously implanted 
into nude mice. 
Constructs (n=6) were implanted into the back of nude mice (Female, 6 weeks 
old, Balb/c; Harlan), with an n=9 per group. Mice were weighed and anesthetized 
with an intraperitoneal injection of xylazine (10 mg kg-1) (Chanazine 2%; Chanelle) 
and ketamine (100 mg kg-1) (Narketan; Vetoquinol). Skin incisions were made along 
 
the central line of the spine. Three constructs were inserted in each subcutaneous 
pocket, and sutured using 4-0 Vicryl plus (Ethicon, Johnson & Johnson) and tissue 
glue (Vetloc xcel). Euthanasia was performed 4 weeks after the surgery by CO2 
inhalation  (confirmed by cervical  dislocation),  and  the  constructs  were  analyzed 
histologically, immunohistochemically, and biochemically. The protocol was reviewed 
and approved by Trinity College Dublin ethics committee. 
 
2.10.  Statistical analysis 
 
 
Results are presented as mean ± standard deviation. Statistical analysis was 
performed with MINITAB 15.1 software package (Minitab Ltd., Coventry, UK). 
Experimental groups were analyzed for significant differences using a general linear 
model for analysis of variance (ANOVA) with factors including concentration, 
crosslinking technique and growth factor supplementation. Tukey’s test for multiple 
comparisons was used to compare conditions. Significance was accepted at a level 
of p<0.05.
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3. RESULTS 
 
 
3.1. Chondro-permissive scaffolds with a consistent structure and pore size 
can be produced using cryomilled cartilage extracellular matrix (ECM) 
 
Scaffold pore size has been shown to regulate stem cell proliferation and 
differentiation. [13,23] Hence, we first sought to develop a method to produce scaffolds 
from cartilaginous ECM with controllable and consistent pore size and shape. Porous 
scaffolds were produced using slurries of either coarse (ECM blended using a 
homogeniser) (Figure 1A) or fine (cryomilled ECM) porcine cartilage ECM (Figure 
1B). The coarse ECM slurry contained particles with a mean size of 322±195 µm, 
while the fine slurry contained particles with a mean pore size of 97±26 µm. Large 
cartilage particles were still present in the freeze-dried scaffold fabricated using the 
coarse slurry (Figure 1C), while a scaffold with a more homogenous pore size and 
morphology was produced using the fine particulated cartilage ECM slurry (Figure 
1D). This was confirmed using helium ion microscopy, where more homogenous and 
spherical  pores  (mean  diameter  -  65±20  µm)  were  observed  in  the  fine  ECM 
scaffolds (Figure 1F), whilst less spherical pores and a wider distribution of pore 
sizes (mean diameter - 104±49 µm) was observed in the coarse ECM scaffolds 
(Figure 1E). 
We next sought to compare the capacity of both coarse and fine cartilage 
ECM-derived scaffolds to promote chondrogenesis of human FPSCs. Tissues 
engineered using both coarse and fine ECM-derived scaffolds stained similarly for 
sGAG and collagen deposition after 28 days in culture (Figure 2A, B). There was no 
significant difference in the sGAG and collagen content of tissues engineered using 
the two different scaffold types (data not shown).
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3.2. The porosity of cartilage ECM-derived scaffolds can be tailored by varying 
the concentration of the slurry 
 
As the fine (or cryomilled) cartilage ECM particles could be used to produce 
scaffolds with a consistent pore size and shape, we next sought to determine how 
the concentration of such slurries would influence the  pore size of the resulting 
scaffolds. HIM demonstrated that varying the ECM slurry concentration (250, 500 
and 1000 mg ml-1) led to the development of scaffolds with different pore sizes 
(Figure 3). Specifically, lowering the concentration of ECM led to the development of 
scaffolds with a higher mean pore size (from 32±12 µm to 65±20 µm; Figure 3D). 
The   bulk   compressive   modulus   of   the   dry   scaffolds   increased   with   ECM 
concentration (Figure 3E); although they become noticeably softer when hydrated. 
The sGAG content of the 250, 500 and 1000 mg ml-1  scaffold was 58.5±6.5 µg, 
191.0±8.0 µg, and 230.0±11.0 µg respectively; while the residual DNA content of the 
 
250, 500 and 1000 mg ml-1 scaffold was 11.0±1.0 µg, 25.0±1.0 µg and 38.0±7.0 µg 
respectively. 
 
3.3. Stem   cell   migration,   proliferation   and   chondrogenic   differentiation 
depends on the porosity of ECM-derived scaffolds 
 
FPSCs were then seeded onto scaffolds fabricated using a range of slurry 
concentrations/pore sizes to determine their capacity to facilitate FPSC migration, 
proliferation and subsequent chondrogenesis. Confocal microscopy revealed that 
FPSCs were evenly distributed throughout the 250 mg ml-1  scaffolds after 1 day of 
culture (Figure 4A), while cells were only observed around the periphery of the lower 
pore size 500 and 1000 mg ml-1  scaffolds (Figure 4B, C). After 28 days of culture, 
FPSCs were observed throughout the majority of the 250 and 500 mg ml-1 scaffolds, 
 
except for a region in the very centre of the 500 mg ml-1 scaffold, while viable cells
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were only observed around the periphery of the 1000 mg ml-1  scaffolds. Greater 
FPSC proliferation was also observed within the 250 mg ml-1 scaffolds, as evidenced 
by a significant increase in DNA content (164%, p<0.05) within this scaffold over 28 
days in culture, whilst no significant change in DNA content was observed in the 500 
and 1000 mg ml-1 scaffolds. 
Histological analysis (nuclear fast red nuclei staining) on day 0, 7, 14 and 28 
of culture confirmed that FPSCs were homogenously distributed throughout the 250 
mg ml-1 scaffold (Figure 5A). Furthermore, robust proteoglycan deposition was 
observed throughout this construct by day 28 (Figure 5A, D).  In contrast, the lower 
pore sized 1000 mg ml-1 scaffolds stained less intensely and more inhomogeneously 
for Alcian Blue compared to other constructs. This was confirmed by biochemical 
 
analysis of the sGAG content of the engineered tissues, which demonstrated greater 
levels of ECM accumulation within the 250 mg ml-1 scaffolds (Figure 5). The greater 
levels of cellular infiltration and proliferation within the lower concentration scaffolds 
(Figure  4,  5)  likely  contribute  to  these  higher  levels  of  sGAG  accumulation.  In 
addition, the 250 mg ml-1 constructs were stiffest after 28 days in culture (Figure 5F). 
Based on  these  results,  the  250  mg  ml-1  fine  scaffold  was  selected  for further 
 
development in the remainder of the study. 
 
 
3.4. EDAC  crosslinking  of  ECM-derived  scaffolds  prevented  cell  mediated 
contraction with no loss in chondro-inductive capacity 
 
A  potential  limitation  of  the  lower  concentration  cartilage  ECM-derived 
scaffolds was that they underwent greater levels of contraction during culture 
compared to higher concentration scaffolds (data not shown). Previous studies have 
demonstrated that EDAC crosslinking is an efficient way to minimize cell mediated 
contraction in scaffolds for cartilage tissue engineering applications.[5,7]  Therefore,
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250 mg ml-1  scaffolds were physically crosslinked using DHT and chemically with 
EDAC. Significantly less contraction was observed in scaffolds that underwent both 
EDAC and DHT crosslinking (Figure 7A, B). The diameter of the EDAC crosslinked 
scaffolds did not change over 28 days in culture, and was significantly higher than 
the DHT only crosslinked scaffolds. 
The next step was to assess and confirm that the chondro-inductivity of the 
scaffolds was not affected by the use of EDAC crosslinking. Histological analysis 
revealed that robust levels of cartilage ECM deposition occurred within both EDAC 
plus DHT (Figure 7B) and DHT only (Figure 7A) crosslinked scaffolds. Furthermore, 
the sGAG content of DHT plus EDAC scaffolds was significantly higher than that of 
DHT only constructs (Figure 7C), confirming that EDAC crosslinking does not 
suppress chondrogenesis within cartilage ECM-derived scaffolds. 
 
3.5. EDAC crosslinking delays the burst release of TGF-β3 from cartilage ECM- 
derived scaffolds 
 
We have previously demonstrated that cartilage ECM-derived scaffolds 
(derived from coarse ECM particles) can be used as platforms to control the release 
of soak loaded growth factor and consequently induce robust chondrogenesis of 
FPSCs.[7]  To confirm that cartilage ECM-derived scaffolds derived from a slurry of 
fine particles can also be used to control the release of exogenously supplied TGF- 
β3, and to evaluate the impact of EDAC crosslinking on growth factor release, an 
ELISA was performed to determine the release of TGF-β3 into the media (Figure 
8B). After 4 days of culture, the media of the EDAC plus DHT crosslinked scaffolds 
contained significantly lower levels TGF-β3 compared to the DHT-only crosslinked 
scaffold. Both scaffolds released almost all of the TGF-β3 loaded onto the scaffold 
within the first 10 days of the culture period.
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The next goal was to confirm that loading of TGF-β3 onto the scaffold could 
induce at least comparable chondrogenesis to directly supplementing the culture 
media with this growth factor. Both the DHT and DHT plus EDAC crosslinked 
scaffolds that were soak loaded with TGF-β3 were capable of inducing robust 
chondrogenesis of FPSCs, as evidenced by alcian blue, picro-sirius red and type II 
collagen immunohistochemical staining (Figure 8A, B).   The sGAG content of 
constructs after 28 days of culture was higher for DHT crosslinked scaffolds when 
soak loaded with TGF-β3 (Figure 8A) compared to scaffolds where the media was 
directly supplemented with TGF-β3. A similar trend was observed for DHT plus 
EDAC crosslinked scaffolds (Figure 8A). 
3.6. Coupling freshly isolated CD44+ infrapatellar fat pad derived stromal cells 
with a TGF-β3 eluting cartilage ECM-derived scaffold promotes 
chondrogenesis in vivo 
 
We next sought to evaluate whether a TGF-β3 eluting cartilage ECM-derived 
scaffold, optimized in vitro to promote stem cell proliferation and chondrogenic 
differentiation,    could  be  used  to  promote  chondrogenesis  of  culture  expanded 
FPSCs in vivo. To this end, cell-free and FPSC-loaded constructs were implanted 
subcutaneously into nude mice. After 28 days in vivo, cell free scaffolds had been 
infiltrated with host cells that synthesised a fibrous or fibrocartilaginous tissue.  The 
pores of ECM-derived scaffolds seeded with culture expanded FPSCs stained more 
intensely for glycosaminoglycan (Alcian Blue) and type II collagen deposition 
compared to cell-free constructs (Figure 9C, D). With the ultimate objective of 
developing a single-stage therapy for articular cartilage regeneration, we next sought 
to determine if freshly isolated (i.e. not culture expanded) infrapatellar fat pad derived 
stromal cells, seeded into the same TGF-β3 eluting cartilage ECM-derived scaffold,
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could be used as an alternative to culture expanded FPSCs to promote 
chondrogenesis in vivo.  The tissue formed in constructs seeded with freshly isolated 
FPSCs was comparable to that within cell-free constructs, suggesting that this cell 
population  was  not  capable  of  undergoing  robust  chondrogenesis  within  the 
scaffolds in vivo. Given that the infrapatellar fat pad contains a heterogeneous cell 
population,  we  finally  sought  to  determine  if  freshly  isolated  CD44+   (a  putative 
marker of chondro-progenitors) fat pad derived stromal cells would promote more 
robust chondrogenesis in vivo. Cartilage-like matrix deposition was observed 
throughout CD44+  cell seeded constructs, with localized regions staining intensely 
for sGAG and type II collagen deposition (Figure 9I, J). 
 
4.  DISCUSSION 
 
 
The overall goal of this study was to develop a  single-stage strategy for 
promoting chondrogenesis in vivo consisting of an optimised cartilage ECM-derived 
scaffold and freshly isolated infrapatellar fat pad derived stromal cells. By freeze- 
drying slurries of cryomilled cartilage ECM of differing concentrations, it was possible 
to produce scaffolds with a range of pore sizes. The migration, proliferation and 
chondrogenic differentiation of FPSCs depended on the concentration/porosity of the 
ECM-derived scaffolds, with greater sGAG accumulation observed within the 
scaffolds with a larger pore size. A limitation of these more porous scaffolds was that 
they underwent greater cell-mediated contraction. However this could be prevented 
with   the   use   of   combined   dehydrothermal   (DHT)   and   1-Ethyl-3-3dimethyl 
aminopropyl carbodiimide (EDAC) crosslinking, with no loss in scaffold  chondro- 
inductive capacity. Such crosslinking also functioned to retard the initial release of 
exogenously loaded TGF-β3 from stem cell seeded scaffolds.  Finally, the optimized 
scaffold  was  seeded  either  with  culture  expanded  FPSCs  or  freshly  isolated
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infrapatellar fat pad derived stromal cells and implanted subcutaneously into nude 
mice. The results of this study demonstrate that a cartilage ECM-derived scaffold 
loaded with TGF-β3 supports cartilage-like tissue formation in vivo, specifically when 
seeded with culture expanded FPSCs or freshly isolated CD44+ stromal cells. These 
findings open up the possibility of using freshly isolated CD44+ stromal cells from the 
infrapatellar  fat  pad  of  the  knee  as  part  of  a  single-stage  therapy  for  joint 
regeneration. 
Freeze-drying slurries of fine (cryomilled) cartilage ECM particles was found to 
result in the development of scaffolds with a consistent pore size and morphology. 
Similar strategies have been employed in the literature to particulate ECM.[24] From a 
translational perspective, the identification of robust and consistent strategies for 
scaffold fabrication will be important, for example, by leading to the development of 
production methods that minimise batch-to-batch variability. In addition, modifying 
ECM  particles  size  may  also  influence  the  efficacy  of  the  resulting  scaffold  to 
facilitate tissue regeneration. For example, previous studies have demonstrated that 
the particle size of powdered ECM material can influence new tissue forming fate, 
despite the fact that similar proteins were found in both biomaterials.[25] In the current 
study, the chondro-inductive properties of cartilage ECM-derived scaffold were found 
to be independent of particle size, i.e. it was similar for both coarse and fine cartilage 
ECM-derived scaffolds. What remains unclear at this stage is how the devitalization 
and scaffold fabrication process affects the composition of the ECM (e.g. sGAG and 
collagen content relative to native tissue). In addition, while the devitalization process 
used in this study will disrupt cellular structures, DNA and other cellular components 
that remain within the ECM that may elicit an immune response in vivo. Further work 
needs   to   be   done   to   determine   immunogenicity   of   chondral   ECM-derived
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materials,[11]  and to optimise the decellularization of such matrices to facilitate their 
clinical translation. 
Reducing the ECM concentration led to the development of scaffolds with a 
larger pore size, which in turn enhanced cellular infiltration, proliferation and 
chondrogenic differentiation. Previous studies have also reported that the porosity of 
ECM-derived scaffolds depend on slurry ECM concentration.[9] It is still unclear as to 
what the ideal scaffold pore size is for facilitating cell attachment, proliferation and 
migration in tissue engineering, with a wide range (5 to 500 μm) utilized in the 
literature depending on the cell type.[26]  In the context of stem cell differentiation, it 
has been demonstrated that chondrogenesis is enhanced in poly (ε-caprolactone) 
(PCL) scaffolds with a larger pore size.[27] Within osteochondral defects, it has been 
demonstrated that cell-seeded poly(lactide-co-glycolide) (PLGA) scaffolds with 100- 
200 μm pores in the chondral layer and 300-450 μm pores in the osseous layer best 
supported joint regeneration.[28]  In addition to pore size, scaffold stiffness has also 
been  shown  to  regulate  stem  cell  differentiation,  with  softer  scaffolds  shown  to 
support chondrogenesis, and stiffer scaffolds shown to support osteogenesis.[17] 
Therefore the enhanced chondrogenesis observed in the higher porosity/lower 
concentration ECM-derived scaffolds observed in this study may be due, at least in 
part,  to  alterations  in  scaffold  stiffness  as  the  concentration  of  the  scaffold  is 
reduced. Additional mechanical testing on individual scaffold struts is required to 
further test this hypothesis. Scaffold composition can also influence its degradation 
kinetics and hence the release rates of biochemical cues,[29] which could also 
contribute to the altered levels of chondrogenesis observed in different 
concentration/porosity ECM-derived scaffolds.
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In agreement with previous studies, we found that EDAC crosslinking 
prevented contraction of cartilage ECM-derived scaffolds.[7]  It was also found that 
sGAG accumulation was greater within EDAC plus DHT crosslinked scaffolds 
compared with the DHT only scaffolds, likely due to superior sGAG retention within 
this construct. Further in vivo studies are also necessary to examine other impacts of 
EDAC, including the immunological response.[24] 
A further impact of EDAC crosslinking was the delay in the initial release of 
 
TGF-β3 from the scaffold. Previous studies have demonstrated that  altering the 
degree of crosslinking of collagen-like micro-spheres affects the release profile of 
growth factors such as TGF-β.[30] Irrespective of the degree of scaffold crosslinking, 
the majority of the growth factor was released from the ECM-derived scaffolds within 
the first 10 days of culture. Superior chondrogenesis was also observed in scaffolds 
loaded with TGF-β3 compared to constructs where the growth factor was directly 
added to the media, despite the fact that a much lower amount of TGF-β3 was soak 
loaded onto these scaffolds (5ng) compared to what was added to the media over 
the 4 week culture period (~200ng). This may be explained by the temporal release 
of TGF-β3 from the scaffold, as a number of studies have demonstrated that short- 
term exposure to growth factors enhances chondrogenesis.[31] These results provide 
further support for the concept that ECM-derived scaffolds can release growth factor 
within an optimal dosing window to effectively promote chondrogenesis of stem 
cells.[7]  Further studies are required to identify the optimal concentration of TGF-β 
that needs to be added to cartilage ECM-derived scaffolds to promote robust 
differentiation of embedded cells. Given previous studies which suggest that such 
cartilage  ECM  derived  materials  may  be  chondro-inductive  suggests  that  only
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relatively low levels of growth factor may need to be added to these scaffolds to 
facilitate the development of hyaline cartilage.[8, 9, 11, 32] 
Cartilage ECM-derived scaffolds were found to support chondrogenesis of 
culture expanded infrapatellar fat pad derived stem cells in vivo. Cell free scaffolds 
were infiltrated by host cells, however when compared with stem cell seeded groups 
a more fibrous or fibrocartilaginous tissue was generated. This is in agreement with 
previous  studies  which  demonstrate  that  stem  cell  seeded  constructs  promote 
superior matrix formation in a similar in vivo model.
[33] 
In the context of developing a 
 
single-stage therapy for cartilage repair, freshly isolated CD44+ infrapatellar fat pad 
derived stromal cells were also found to generate a cartilage-like tissue in vivo when 
seeded onto a cartilage ECM derived scaffold. Enrichment of stromal/stem cells 
based on specific cell surface markers (e.g. CD44, CD90 and CD105) has gained 
increased attention for tissue engineering and regenerative medicine applications.[34] 
CD44 is the principal cell surface receptor for hyaluronate, a key component of 
articular cartilage, making it an interesting target for isolating cell populations with a 
strong chondrogenic potential.[35]  CD44 antibody-beads have previously been used 
for stem cell isolation and delivery, and such complexes have been shown to 
effectively generate chondrogenic matrix in monolayer and 3D culture.[36]     A key 
finding of this study is that CD44 antibody enrichment can also be used to help 
isolate a large population of chondro-progenitor cells from freshly digested 
infrapatellar fat pad,  a tissue known to contain an abundant number of  stromal cells 
with a high expression of CD44.[37] Critically, this freshly isolated CD44+ subset from 
the fat pad appeared to  undergo  comparable chondrogenesis  in  vivo  to culture 
expanded FPSCs when seeded onto cartilage ECM derived scaffolds. Such a 
strategy  for  the  enrichment  and  chondrogenic  differentiation  of  freshly  isolated
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stromal  cells  will  be  of  crucial  importance  for  the  development  of  single-stage 
procedures for cartilage regeneration. 
 
5. CONCLUSION 
 
 
In conclusion, this study describes a robust method to control the composition 
and porosity of cartilage ECM-derived scaffolds, a biomaterial with potent pro- 
chondrogenic properties. By seeding such a scaffold with either culture expanded 
infrapatellar fat pad derived stem cells, or freshly isolated CD44+ stromal cells, it was 
possible to promote the development of a cartilage-like tissue in vivo. This latter 
finding supports the concept that enriched populations of freshly isolated stromal 
cells, when combined with a chondro-inductive scaffold, can induce cartilage 
formation and can potentially be used in one-step or single-stage procedures for 
cartilage repair. The clinical realisation of such a strategy would overcome many of 
the limitations believed to be hampering the widespread clinical adoption of current 
cell-based approaches such as autologous chondrocyte implantation. 
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8. FIGURES 
 
 
 
 
Figure 1 – Light micrographs of cartilage slurries: coarse (A, C) and fine (B, D) 
before and after freeze-drying (FD) (scale bar: 500 μm). Helium ion micrographs of 
cartilage ECM-derived scaffolds produced using either a   coarse (E) and   fine (F) 
slurry (scale bar: 100 μm). 
 
 
 
 
Figure 2 –Alcian blue (AB), picro-sirius red (PR) and collagen type II (Coll II) staining 
of ECM-derived scaffold produced using a coarse (A) or fine (B) slurry, after 28 days 
of culture (scale bar: 50µm).
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Figure 3 – (A-C) Helium ion microscopy (HIM) micrographs of scaffolds with altered 
cartilage ECM slurry concentrations: (A) 250 mg/ml; (B) 500 mg/ml; (C) 1000 mg/ml 
scaffolds (scale bar: 100 µm). (D) Mean scaffold pore size (ap˂0.05; a indicates a 
significant difference to the 1000 mg/ml group). (E) Young’s Modulus for each dry 
scaffold at day 0 (n=3; ***p˂0.001). 
 
 
 
 
Figure 4 – (A-C) Confocal microscopy at day 1 of human infrapatellar fat pad derived 
stem cells seeded in ECM-derived scaffolds; calcein was used to stain live cells: (A) 
250 mg/ml, (B) 500 mg/ml and (C) 1000 mg/ml. (D-F) Scaffolds at day 28:  (D) 250 
mg/ml, (E) 500 mg/ml and (F) 1000 mg/ml scaffolds. Images represent a cross- 
section through ECM-derived constructs (scale bar: 2 mm).
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Figure 5 – Histological sections staining for glycosaminoglycans (sGAG) (alcian 
blue) and cell nuclei (nuclear fast red) in 250, 500 and 1000 mg/ml ECM-derived 
scaffolds (seeded with FPSCs) at day 0, 7, 14 and 28 of culture (A). (B-D) High 
magnification images demonstrating more robust sGAG deposition within the 250 
mg/ml scaffolds (B) compared to the 500 (C) 1000 mg/ml (D) scaffolds (scale bar: 50 
µm). sGAG accumulation for day 28 (E)  and Young’s modulus for day 28 (F), within 
the 250, 500 and 1000 mg/ml scaffolds (n=4, *p˂0.05). 
 
 
 
 
Figure 6 – (A) Diameter of ECM-derived scaffolds that had been crosslinked with 
DHT or DHT and EDAC after 28 days in culture (n=4, *p<0.05). (B) Macroscopic 
images of scaffolds (yellow represents initial diameter: 5 mm).
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Figure 7 – Alcian blue (AB), picro-sirius red (PR) and collagen type II (Coll II) staining 
of ECM-derived scaffolds after 28 days of culture.   (A) Dehydrothermal (DHT) 
crosslinking; (B) DHT + 1-Ethyl-3-3dimethyl aminopropyl carbodiimide (EDAC) 
crosslinking (scale bar: 50 µm). (C) sGAG and (D) collagen accumulation within DHT 
and DHT+EDAC crosslinked ECM-derived scaffolds   seeded with human FPSCs 
(n=4, *p˂0.05).
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Figure 8 – (A) sGAG accumulation after 28 days in culture for scaffolds soak-loaded 
with TGF-β3 (TGF-soak load/scaffold) compared to constructs where  TGF-β3 was 
added to the media (TGF-media) Scaffolds with and without EDAC crosslinking were 
analysed (n=4, *p˂0.05). (B) TGF-β3 release into the media from TGF-β3 loaded 
ECM-derived scaffold with and without EDAC crosslinking (n=6, *p˂0.05). (C, D) 
Alcian blue (AB), picro-sirius red (PR) and collagen type II (Coll II) staining of ECM- 
derived scaffold loaded with TGF-β3 for DHT (C) and DHT+EDAC (D) crosslinked 
scaffolds after 28 days of culture (scale bar: 50µm).
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Figure 9 – Alcian blue (AB) and collagen type II (Coll II) histological staining for day 0 
before implantation (A and B), implanted cell free scaffolds (C and D respectively), 
expanded FPSC seeded constructs (E and F), freshly isolated fat pad stromal cell 
seeded constructs (G and H) and freshly isolated CD44+ stromal cell seeded 
constructs (I and J). All groups were implanted in vivo for four weeks (scale bar: 
50µm). 
